Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000937
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 5
---
 under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares to
the Purchaser. The Company expects that any proceeds received by the Company from such sales to the Purchaser will be used to fund its
development program, for working capital and other general corporate purposes.

The
Company has the right to terminate the Purchase Agreement at any time, upon one business day’s notice, at no cost or penalty. During
any “suspension event” under the Purchase Agreement, the Purchaser does not have the right to terminate the Purchase Agreement;
however, the Company may not initiate any regular or other purchase of shares by the Purchaser, until such event of default is cured.
In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate in
accordance with the terms of the Purchase Agreement.

Registration Rights Agreement

Concurrent
with the execution of the Purchase Agreement, the Company entered into a registration rights agreement with the Purchaser (the “Registration
Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement on Form F-1
with the SEC covering the resale of the Securities, on or before the 45th calendar day following the date of the Registration Rights Agreement
and to use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC at the earliest
practicable date, subject to limited exceptions described therein. The registration rights granted under the Registration Rights Agreement
are subject to certain conditions and limitations and are subject to customary indemnification and contribution provisions.

The
foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are qualified
in their entirety by reference to the full text of such agreements, copies of which are attached hereto as Exhibits 10.1 and 10.2, respectively,
and each of which is incorporated herein in its entirety by reference. The representations, warranties and covenants contained in such
agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such
agreements and may be subject to limitations agreed upon by the contracting parties.

| 3 |

In
the Purchase Agreement, the Purchaser represented to the Company, among other things, that it is an “accredited investor”
(as such term is defined in Rule 501(a)(3) of Regulation D promulgated under the Securities Act of 1933